Dr. Agarwal's Health Care Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AGARWALEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 0.9 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Agarwal's Health Care Limited reported strong FY2026 results with total income surging 20.9% YoY to ₹2,125 crores, crossing the ₹2,000 crore milestone for the first time. Revenue from operations grew 21.6% to ₹2,080 crores, driven by 57 new facility additions taking the network to 288 facilities across 10 countries. EBITDA increased 22.2% to ₹614 crores with margins at 28.9%, while profit after tax jumped 52.4% to ₹168 crores. The company performed 323,245 surgeries during the year (up 14.5% YoY). For Q4 FY2026, total income was ₹577 crores (up 21.2% YoY) with PAT of ₹50 crores (up 17.4% YoY). The Board also approved reallocation of ₹14.88 crore unspent IPO proceeds from issue expenses to general corporate purposes. Statutory auditors S.R. Batliboi & Associates LLP issued an unmodified opinion.
Strong all-round growth with PAT up 52% demonstrates operational leverage. The stock is likely to see positive sentiment given consistent delivery across revenue, EBITDA and profit metrics, with margin expansion also indicating improving efficiency.